Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says

RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential

RBC Capital analyst Michael J. Yee defended XenoPort (NASDAQ: XNPT) amid weakness following the release of '829 data, saying shares are close to a floor, while noting potential M&A.

"Psoriasis data shows clear efficacy as we expected but undifferentiated GI side effects vs other fumarates and CELG Otezla. But if the market cap is $315M now and there is at least theoretical $200-300M + of takeout value on Horizant ($4-5/share), then Horizant could be cheap or '829 is... More

XenoPort's (XNPT) XP-829 Efficacy 'Looks Good' - RBC Capital

RBC Capital maintained an Outperform rating on XenoPort (NASDAQ: XNPT) with a price target of $10. Earlier XenoPort announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. Analyst Michael J. Yee... More

XenoPort (XNPT) Announces Significant Prelim. Top-Line Data from XP23829 Phase 2 in Psoriasis

XenoPort (NASDAQ: XNPT) announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically significant improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to currently... More